Poniard halves workforce and struggles on with picoplatin
This article was originally published in Scrip
Poniard Pharmaceuticals is to reduce its workforce by more than a half to 21 employees and is focusing all remaining resources to advance the ongoing clinical development of its anticancer picoplatin.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.